[go: up one dir, main page]

DK1893213T3 - Combination of pyrimidylaminobenzamide compounds and imatinib to treat or prevent proliferative diseases - Google Patents

Combination of pyrimidylaminobenzamide compounds and imatinib to treat or prevent proliferative diseases

Info

Publication number
DK1893213T3
DK1893213T3 DK06760628.5T DK06760628T DK1893213T3 DK 1893213 T3 DK1893213 T3 DK 1893213T3 DK 06760628 T DK06760628 T DK 06760628T DK 1893213 T3 DK1893213 T3 DK 1893213T3
Authority
DK
Denmark
Prior art keywords
combination
imatinib
treat
proliferative diseases
prevent proliferative
Prior art date
Application number
DK06760628.5T
Other languages
Danish (da)
Inventor
Leila Alland
Paul W Manley
Juergen Mestan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1893213T3 publication Critical patent/DK1893213T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides a pharmaceutical combination comprising: a) a pyrimidylaminobenzamide compound, and b) imatinib. and a method for treating or preventing a proliferative disease, especially GIST, using such a combination.
DK06760628.5T 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib to treat or prevent proliferative diseases DK1893213T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68775805P 2005-06-03 2005-06-03
PCT/US2006/021307 WO2006132930A1 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Publications (1)

Publication Number Publication Date
DK1893213T3 true DK1893213T3 (en) 2010-06-07

Family

ID=36968749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06760628.5T DK1893213T3 (en) 2005-06-03 2006-06-02 Combination of pyrimidylaminobenzamide compounds and imatinib to treat or prevent proliferative diseases

Country Status (26)

Country Link
US (2) US7767688B2 (en)
EP (1) EP1893213B1 (en)
JP (2) JP5281887B2 (en)
KR (1) KR101276425B1 (en)
CN (1) CN101180060B (en)
AT (1) ATE457727T1 (en)
AU (1) AU2006255559B2 (en)
BR (1) BRPI0611506A2 (en)
CA (1) CA2608814C (en)
CY (1) CY1110027T1 (en)
DE (1) DE602006012313D1 (en)
DK (1) DK1893213T3 (en)
ES (1) ES2339593T3 (en)
HR (1) HRP20100265T1 (en)
IL (1) IL187408A0 (en)
MA (1) MA29565B1 (en)
MX (1) MX2007015159A (en)
NO (1) NO20080037L (en)
NZ (1) NZ563446A (en)
PL (1) PL1893213T3 (en)
PT (1) PT1893213E (en)
RU (1) RU2430727C2 (en)
SI (1) SI1893213T1 (en)
TN (1) TNSN07453A1 (en)
WO (1) WO2006132930A1 (en)
ZA (1) ZA200709473B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608814C (en) * 2005-06-03 2013-09-03 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
EP2382976A1 (en) * 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CN102719530B (en) * 2012-05-07 2013-11-06 厦门艾德生物医药科技有限公司 Primer, probe and kit used for detecting PDGFR alpha gene mutations
KR101386697B1 (en) 2012-06-18 2014-04-18 아주대학교산학협력단 Composition for preventing or treating vascular permeability disease comprising imatinib or pharmaceutically acceptable salts thereof as active ingredient
US20200206223A1 (en) 2017-07-26 2020-07-02 Ftf Pharma Private Limited Liquid dosage forms of imatinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042042A1 (en) * 2002-11-15 2005-06-08 Sugen Inc COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS
CA2608814C (en) * 2005-06-03 2013-09-03 Novartis Ag Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases

Also Published As

Publication number Publication date
AU2006255559A1 (en) 2006-12-14
US7767688B2 (en) 2010-08-03
US8653093B2 (en) 2014-02-18
ES2339593T3 (en) 2010-05-21
KR20080021633A (en) 2008-03-07
PT1893213E (en) 2010-04-19
EP1893213B1 (en) 2010-02-17
BRPI0611506A2 (en) 2010-09-14
EP1893213A1 (en) 2008-03-05
HRP20100265T1 (en) 2010-06-30
ATE457727T1 (en) 2010-03-15
JP2013035853A (en) 2013-02-21
PL1893213T3 (en) 2010-08-31
CY1110027T1 (en) 2015-01-14
IL187408A0 (en) 2011-07-31
MA29565B1 (en) 2008-06-02
CA2608814A1 (en) 2006-12-14
JP5281887B2 (en) 2013-09-04
CA2608814C (en) 2013-09-03
NZ563446A (en) 2011-02-25
NO20080037L (en) 2008-01-03
TNSN07453A1 (en) 2009-03-17
JP2008542390A (en) 2008-11-27
KR101276425B1 (en) 2013-06-19
US20100190800A1 (en) 2010-07-29
RU2007147957A (en) 2009-07-20
CN101180060A (en) 2008-05-14
AU2006255559B2 (en) 2009-12-17
ZA200709473B (en) 2008-12-31
CN101180060B (en) 2011-12-28
WO2006132930A1 (en) 2006-12-14
US20080312252A1 (en) 2008-12-18
HK1115528A1 (en) 2008-12-05
RU2430727C2 (en) 2011-10-10
DE602006012313D1 (en) 2010-04-01
MX2007015159A (en) 2008-02-15
SI1893213T1 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
EA200900798A1 (en) INDOL-4-ILPYRIMIDINYL-2-ILAMINE DERIVATIVES AND THEIR APPLICATION AS INHIBITORS OF CYCLIN-DEPENDENT KINASE
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
EA200870415A1 (en) QUINAZOLINS TO INHIBIT PDK 1
DK1984357T3 (en) 2,4-PYRIMIDINE DIAMINE COMPOUNDS FOR TREATMENT OR PREVENTION OF AUTO-IMMUNE DISEASES
EA201001847A1 (en) COMPOUNDS AND COMPOSITIONS APPLICABLE FOR THE TREATMENT OF MALARIA
NO20083002L (en) Method for using CD40 binding compounds
NO20084749L (en) Organic compounds and their applications
EA200900819A1 (en) QUINAZOLINS FOR INHIBITION OF PDK1
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
EA200702048A1 (en) PHARMACOKINETICALLY IMPROVED COMPOUNDS
EA201690265A3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTITUTED ACYLANILIDES
DK1942898T3 (en) Dipeptidyl peptidase inhibitors for the treatment of diabetes
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
BRPI0513310A (en) tetrapeptide analogs
CL2007003758A1 (en) COMPOUNDS DERIVED FROM AMINOPIRIMIDINE, INHIBITORS OF PLK1; PHARMACEUTICAL COMPOSITION, USEFUL FOR CANCER TREATMENT.
BRPI0815057A2 (en) Compound, pharmaceutical composition, and method for treating infection.
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
EA201000895A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIZOSOME DISEASES
GT200900065A (en) DERIVED FROM 2-PYRIDINCARBOXAMIDE THAT HAS GK ACTIVATING EFFECT
CL2007003540A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE SERINE PROTEASE OF HEPATITIS C; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
MX2008015775A (en) Compounds and compositions for treatment of cancer.
DK1893213T3 (en) Combination of pyrimidylaminobenzamide compounds and imatinib to treat or prevent proliferative diseases
ATE410166T1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES FOR THE TREATMENT OF INFERTILITY